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Abstract
Background: On the 11th March 2020, the World Health Organization declared the COVID-19 outbreak a
pandemic. Multiple new guidelines were proposed and existing models of social, domestic and hospital care
altered. Most healthcare systems were largely unprepared for this, and the pandemic has tested their adaptability.
This study aimed to assess the impact of COVID-19 on the demographics, presentation, clinical management and
outcomes of patients with proximal femoral (hip) fractures comparing them to a similar cohort of patients admitted
a year earlier.
Methods: This retrospective multi-centre cohort study compared all patients admitted with hip fractures between
1st March and 30th May 2019 (group PC: pre-COVID-19) with hip fracture patients admitted over the same time
period during the pandemic in 2020 (group C: COVID-19). The data was obtained from the hospitals’ local and
National Hip Fracture Databases. Mortality data was checked with the Office for National Statistics (ONS). Primary
outcomes were time to theatre, in-patient length of stay and 30-day mortality.
Results: A total of 580 patients were included (304 group PC, 276 group C). Patient demographics including
Charlson Comorbidity Index and Nottingham Hip Fracture Scores were broadly similar across the two cohorts.
There was a significant reduction in the percentage of total hip replacements (11 to 5%, p = 0.006) in group C.
There was an increase in conservative management (1 to 5%, p = 0.002) in group C. Time to theatre was
significantly delayed in group C (43.7 h) vs group PC (34.6 h) (p ≤ 0.001). The overall length of hospital stay was
significantly longer in group PC (16.6 days) vs group C (15 days) (p = 0.025). The 30-day mortality rate in group C
was 9.8% compared to 8.2% in group PC (p = 0.746), but for COVID-19 (+) patients, it was significantly higher at
38.2% vs 5.8% in COVID-19 (−) patients (p < 0.001).
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Conclusion: This is one of the largest multi-centre comparative cohort study in the literature to date examining the
impact of the COVID-19 pandemic on the management of hip fracture patients. Whilst mortality rates were similar
in both groups, COVID-19-positive patients were almost seven times more likely to die, reflecting the seriousness of
the COVID-19 infection and its sequelae in such elderly, vulnerable patients.
Keywords: Proximal femoral (hip) fracture, COVID-19, Intracapsular hip fracture, Extracapsular hip fracture, 30-day
mortality, Time to theatre, Length of stay
Background
Severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) has spread to most countries in the world, with
the World Health Organization (WHO) declaring a
COVID-19 pandemic on March 11, 2020 [1]. This has
placed enormous strains on National Health Systems
(NHS), leading to significant changes in the way many
conditions are managed [2–7]. In the United Kingdom
(UK), this has led to unprecedented pressures on the
NHS [8]. Even during this pandemic, patients with hip
fractures remain one of the commonest reasons for ad-
missions [9–11]. Over 60,000 hip fractures occur annu-
ally and represent a significant proportion of the trauma
workload for most hospitals [12]. Patients with hip frac-
tures are usually frail and elderly with multiple pre-
existing co-morbidities [13, 14]. Expedited surgery, usu-
ally in the form of fixation, a hemiarthroplasty or total
hip replacement, is usually indicated for most patients,
as this is associated with better outcomes for patients
[15, 16]. Although almost all planned surgery has been
cancelled in the UK during this pandemic [17], the inci-
dence of hip fractures requiring emergency surgical
intervention during this period has remained constant
[9–11]. The British Orthopaedic Association (BOA) is-
sued guidance on how to manage trauma patients in the
COVID-19 situation. They stated that “surgeons will
need to consider alternative ways to manage many as-
pects of urgent orthopaedic conditions and trauma.
Changes to standard management plans may be required
to minimise patient exposure to disease and overall im-
pact on resources” [18].
Our understanding of the impact of COVID-19 on this
population of patients remains limited with a paucity of
clinical data on this subject. An international collabora-
tive study looked at the mortality rates of patients that
were COIVD-19-positive (7 days prior or 30 days after
elective or emergency surgery) and found that the over-
all 30-day mortality rate was 23.8%. Breaking this down,
mortality rates for emergency surgery in these patients
were statistically significantly higher at 25.6% (214/835)
vs elective surgery at 18.9% (53/280). When defining the
surgery by specialty (combining elective and emergency
cases), the COVID-19-positive patients undergoing
orthopaedic surgery had the 5th highest mortality rate
out of 15 specialties at 28.8% (86/299) [19]. Another re-
cently published multi-centre retrospective cohort study
from London comparing COVID-19 positive and nega-
tive hip fracture patients found an increased 30-day
mortality rate of 30.5% (25/82) vs 10.3% (35/340), re-
spectively (p < 0.001) [20].
In response to the COVID-19 pandemic, many hospi-
tals have had to reduce theatre capacity significantly and
to run so-called ‘hot’ and ‘cold’ theatres to accommodate
patients who were COVID-19 positive and negative, re-
spectively. Dedicated trauma lists have stopped due to
redeployment of anaesthetic and theatre staff. Anec-
dotally, the time taken to undertake surgery has in-
creased due to logistical challenges and the need to
minimise the risk of spreading the virus in a high-risk
environment where aerosolised particles are generated
[3, 21–26]. These changes during unprecedented times
are likely to have a significant impact on the ability to
deliver optimal hip fracture care which can impact pa-
tient outcomes.
The aim of this multi-centre study was to assess the
impact of COVID-19 on the demographics, presentation,
clinical management and outcomes of patients with
proximal femoral (hip) fractures comparing them to a
similar cohort of patients admitted a year earlier. This,
to our knowledge, is one of the largest studies of its kind
to assess the impact of the COVID-19 pandemic on hip
fracture trauma services in England and provides vital
information for the continued management of these pa-
tients in the current situation and to help prepare for fu-
ture pandemics.
Methods
A multi-centre retrospective observational study was
undertaken in three hospitals in England, which in-
cluded two large district general hospitals (DGH) and
one major trauma centre (MTC). One of the DGH (hos-
pital A) was based in the West Midlands, with the other
DGH (hospital B) and the MTC (hospital C) based in
Yorkshire. In total, the three hospitals serve a population
of over 1.8 million people.
This study was registered with each of the hospitals as
a service evaluation study and compared all patients ad-
mitted with proximal femoral fractures between 1st
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March and 30th May in 2019 (group PC: pre-COVID-
19) to patients of the same diagnosis admitted over the
same time period during the pandemic in 2020 (group
C: COVID-19). The data was obtained from the hospi-
tals’ local and National Hip Fracture Databases (NHFD).
Mortality data was checked with the Office for National
Statistics (ONS). The primary outcomes were 30-day
mortality, time to theatre and in-patient length of stay.
Patients were tested for COVID-19 with throat and
nose swab assays using reverse transcriptase polymerase
chain reaction (RT-PCR) for SARS-CoV-2. In hospital B,
all patients were tested. Initially, patients admitted to
hospitals A and C were only tested for COVID-19 if
there were indications to do so according to local hos-
pital guidelines: presence of new cough, fever (> 37.8°),
acute respiratory infection, acute worsening of under-
lying respiratory illness and COVID-19 radiological
changes (bilateral CXR infiltrates). However, by the end
of April, both of these hospitals were testing all patients
on admission for COVID-19 as per hospital protocols.
Overall, 58% (46/79) and 83% (111/134) of patients in
hospital A and C, respectively, were tested for COVID-
19. Patients were therefore classified as COVID-19 nega-
tive if they were asymptomatic or had a negative throat
and nose swab. Patients were classified as COVID-19
positive in the presence of clinical symptoms and/or a
positive throat and nose swab at any time point during
their in-hospital stay. Repeat swab samples were per-
formed in patients with negative swab assay results with
persistent or new suspicious clinical features. The mini-
mum interval between swab samples was 24 h, and all
swab samples were obtained by local nursing staff.
The following data were recorded for all patients: pa-
tient demographics and baseline characteristics (age,
gender, laterality of surgery, American Society of Anes-
thesiologists (ASA) grade), preoperative factors (Charl-
son Comorbidities Index (CCI), Nottingham Hip
Fracture Score (NHFS), mobility status, social situation,
comorbidities), operative factors (fracture type, operative
intervention performed) and patient outcomes (time to
theatre, mortality at 30 days, length of hospital stay).
Additionally, for patients in group C, the presence of
COVID-19 symptoms and RT-PCR SARS-CoV-2 swab
results (if taken) were noted.
General descriptive analysis was performed for both
time periods in groups PC and C. Continuous variables
were reported using means and standard deviations (SD)
if they followed a normal distribution; otherwise, the
median and range were used. Absolute frequencies and
proportions (as a percentage) were used to summarise
categorical variables. To compare the two groups, where
the data was parametric, the Students t test and Pearson
chi-squared analysis were employed. Where the data was
nonparametric, the Mann-Whitney U test was applied.
For all analyses, the statistical package STATA version
13.1 (StataCorp. 2013. Stata Statistical Software: Release
13. College Station, TX: StataCorp LP) was used. p value
of 0.05 assumed to be significant.
Results
There were 580 patients included in this study, which
comprised 304 patients in group PC and 276 patients in
group C. There was an average of 3 patients admitted
per day in both group PC (range 1–14 patients per day)
and group C (range 1–10 patients per day). Patient
demographics including gender, CCI, NHFS and fracture
type were similar across the two cohorts. There were
less ASA 3 but more ASA 4 patients in group C com-
pared to group PC. (see Table 1).
Table 2 compares the operations and outcomes of the
two groups. There were no significant differences in the
numbers of dynamic hip screw (DHS) (p = 0.770) and
hemiarthroplasties (p = 0.363) performed. In group C,
there was a significant reduction in the percentage of
total hip replacements (THR) (11 to 5%, p = 0.006) and
an increase in patients managed conservatively (1 to 5%,
p = 0.002). The time to theatre (in hours) was signifi-
cantly longer in group C (43.7) vs group PC (34.6) (p <
0.001). Length of hospital stay was significantly longer in
group PC (16.6 days) vs group C (15 days) (p = 0.025).
The 30-day mortality rate was 9.8% in group C vs 8.2%
in group PC (p = 0.746).
Table 3 shows the patient demographics and outcomes
between COVID-19-positive and COVID-19-negative
Table 1 Patient demographics in the pre-COVID-19 (PC) and
COVID-19 (C) groups
Variable PC (n = 304) C (n = 276) p value
Age, years, mean (SD) 82.4 (10.5) 81.3 (11.2) 0.243
Gender %, M:F 48.7:54.3 51.3:45.7 0.201
ASA, n (%)
1 6 (2.0) 4 (1.5) 0.628
2 71 (23.4) 74 (26.8) 0.337
3 189 (62.2) 140 (50.7) 0.005
4 37 (12.2) 57 (20.7) 0.006
5 1 (0.3) 1 (0.4) 0.945
CCI, mean (SD) 5.5 (2.3) 5.2 (2.1) 0.332
NHFS, mean (SD) 4.7 (1.5) 4.9 (1.7) 0.048
Fracture diagnosis, n (%)
Extracapsular 136 (44.7) 110 (39.9) 0.235
Intracapsular 149 (49.0) 148 (53.6) 0.267
Subtrochanteric 17 (5.6) 6 (2.2) < 0.001
Periprosthetic 2 (0.66) 8 (2.9) < 0.001
Others 0 4 (1.5) < 0.001
SD standard deviation, ASA American Society for Anaesthesiology, M male, F
female, CCI Charlson Comorbidity Index, NHFS Nottingham Hip Fracture Score
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patients in group C. The incidence of COVID-19 was
12.3% (34/276). Within this group, 35% (12/34) were
positive for COVID-19 on admission, 27% (9/34) ac-
quired COVID-19 whilst an inpatient (either the first
swab was negative or they were positive > 14 days post-
admission) and 9% (3/34) tested positive post-admission.
The remaining 29% (10/34) had positive swabs within
14 days of admission and no admission swab; therefore,
it is unknown as to whether these patients were positive
on admission or acquired COVID-19 whilst an inpatient.
For COVID-19-positive patients, the 30-day mortality
rate was significantly higher at 38.2% vs 5.8% in COVID-
19-negative patients (p < 0.001). The COVID-19-positive
patients were older and had a higher NHFS. The time
taken to have surgery was also delayed further in the
COVID-19-positive patients at a mean of almost 55 h,
and the mean length of stay was also significantly longer
(17.6 days).
Discussion
This, to our knowledge, is one of the largest studies in
the literature to date examining the impact of the
COVID-19 pandemic on the management of hip fracture
patients. The average number of hip fracture patients
being admitted per day during the COVID-19 time
period in this study was identical to the pre-COVID-19
time point. This reflects the fact that for these patients,
falls at home or their usual place of residence is the
commonest location when sustaining a hip fracture [27];
therefore, social distancing and isolation do not affect
this. In an observational study in Spain, the number of
hip fracture patients admitted during the COVID-19
pandemic time period was similar to other earlier time
points [11].
The COVID-19 pandemic and subsequent hospital re-
structuring have had a major effect on time to theatre,
length of hospital stay and 30-day mortality rate for
COVID-19-positive hip fracture patients. The BOA
guidance on managing trauma patients in the COVID-
19 situation stated “care of patients with hip and femoral
fractures remains urgent and a surgical priority.” [18].
Taking this into account, patients with an unknown sta-
tus of COVID-19 needing surgery should ideally be
managed as COVID-19-positive patients in ‘hot’ theatres
to avoid delays in awaiting test results. However, this
was difficult to put into practice, due to changes in op-
erative procedures for COVID-19 positive patients, the
extra staff required to run a ‘hot’ theatre and limited the-
atre capacity. This resulted in patients awaiting a
Table 2 Procedures and outcomes in the pre-COVID-19 (PC)
and COVID-19 (C) groups
Variable PC (n = 304) C (n = 276) p value
Operation procedure, n (%)
DHS 75 (24.7) 71 (25.7) 0.770
Hemiarthroplasty 110 (36.2) 110 (39.9) 0.363
THR 33 (10.9) 13 (4.7) 0.006
IM nail 79 (26.0) 55 (19.9) 0.084
ORIF 0 4 (1.5) 0.035
CHS 4 (1.3) 8 (2.9) 0.181
Conservative 3 (1.0) 15 (5.4) 0.002
Time to surgery, h, mean (SD) 34.6 (29.6) 43.7 (34.6) < 0.001
Length of stay, days, mean (SD) 16.6 (10.6) 15.0 (10.6) 0.025
Mortality, n (%) 25 (8.2) 27 (9.8) 0.7456
DHS dynamic hip screw, THR total hip replacement, IM intramedullary, ORIF
open reduction internal fixation, CHS cannulated hip screws, SD
standard deviation
Table 3 Comparing COVID-19-positive vs COVID-19-negative patients in group C
Variable COVID-19 positive (n = 34) COVID-19 negative (n = 242) p value
Age, years, mean (SD) 85.0 (7.7) 80.8 (11.5) 0.043
Gender %, M:F 41.2:58.8 36.5:63.5 0.598
ASA, n (%)
1 0 4 (1.7) 0.449
2 6 (17.7) 67 (27.7) 0.209
3 18 (52.9) 122 (50.4) 0.800
4 10 (29.4) 48 (19.8) 0.182
5 1 (2.9) 0 0.707
CCI, mean (SD) 5.4 (1.4) 5.2 (2.2) 0.355
NHFS, mean (SD) 5.8 (1.5) 4.8 (1.7) 0.001
Time to surgery, h, mean (SD) 54.8 (60.1) 42.1 (29.2) 0.423
Length of stay, days, mean (SD) 17.6 (8.9) 14.7 (10.8) 0.014
Mortality, n (%) 13 (38.2) 14 (5.8) < 0.001
SD standard deviation, ASA American Society for Anaesthesiology, M male, F female, CCI Charlson Comorbidity Index, NHFS Nottingham Hip Fracture Score
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minimum of 24 h for swab results prior to operating.
Delays to theatre during the pandemic were also due to
the following:
1) The requirement to undertake surgery in specific
‘hot’ (COVID-19 positive) and ‘cold’ (COVID-19
negative) theatres.
2) The use of full personal protective equipment (PPE)
during aerosol-generating procedures (AGP) such
as intubation and drilling, in order to reduce the
risk of COVID-19 transmission. This inevitably
meant longer operative (combined anaesthetic and
surgical) times for patients.
3) The reduced availability of theatre capacity as many
theatres were converted to intensive care facilities
in preparation for the expected surge in COVID-19
patients needing ventilatory support.
4) The constantly changing guidelines for operating in
the COVID-19 situation with regard to PPE and
AGPs. Hospitals needed to adapt rapidly to an ever-
changing environment, which led to significant
challenges in theatre capacity and efficiency.
5) The time taken to wear and remove full PPE as well
as the need to have additional staff in theatres with
staff sickness and shielding reducing the available
workforce.
There was a significant difference in the proportion of
THRs and conservative management in the COVID-19
time period, reflecting the advice from the BOA to con-
sider avoiding the more complex option of a THR in
favour of doing a hemiarthroplasty for displaced intra-
capsular hip fractures [18]. Interestingly whilst in our
study, 5% of patients in the COVID-19 era (11% in
2019) had a THR, in the London study by Kayani et al.,
the percentage of patients receiving a THR who were
COVID-19 positive and negative was much higher at
12.2% and 10.9%, respectively [20]. The annual NHFD
2019 report found that less than 10% of patients with a
displaced intracapsular hip fracture had a THR [12].
Similarly, more patients were treated non-operatively as
the risks of surgery were deemed to outweigh the poten-
tial benefits for this select extremely vulnerable group of
patients.
Although the CCI of the patients in the two groups
was comparable, there were significantly more ASA 4
patients in group C (20.1%) compared to group PC
(12.2%). The COVID-19-positive patients also had
higher NHFS, reflecting their greater co-morbidities and
risk of dying after hip fracture. A NHFS of ≤4 is consid-
ered low risk and a score of ≥5 high risk with a 30-day
mortality of 3.5% vs 13.7%, respectively [28]. The reasons
for this are not known, but it could be related to their
delayed presentation or reduced availability of social care
during the COVID-19 period. A larger national study
may be required to test this hypothesis. There was also a
longer time to theatre (which was trending towards stat-
istical significance) in the COVID-19-positive patients.
This is similar to other studies where the time to theatre
was between 2 and 5 days [20, 29].
The NHFD has reported overall national 30-day mor-
tality rates of approximately 6.4% for the time period of
March to May 2019 [30]. In our study, the overall mor-
tality rate for group C across the three units was 9.8%.
Whilst the mortality rates for patients in group PC were
similar to that of those in group C, within group C,
COVID-19-positive patients were almost seven times
more likely to die than COVID-19-negative patients.
This reflects the seriousness of the COVID-19 infection
and its sequelae in such elderly, vulnerable patients.
There have been some small case series studies on the
mortality rates of COVID-19-positive patients with hip
fractures. In a retrospective study of 10 patients in New
York, who were admitted with a hip fracture and were
COVID-19 positive, one patient died at day 19 post-
operatively (10% mortality rate) [31]. One of the earliest
case series from China, looking at 10 patients with a hip
fracture, one of the three patients who was subsequently
found to be COVID-19 positive after their surgery, died
[32]. Two studies from Italy have also reported that the
mortality rates in this group of patients were 31% in a
series of 16 cases [33] and 44% in a cohort of 32 patients
within 21 days of surgery [34]. A multicentre, observa-
tional study in Spain found an early mortality rate of
30.4% in 136 hip fracture patients who were treated sur-
gically or nonoperatively during the COVID-19 pan-
demic [29]. These studies would support our findings of
a mortality rate of 35% in COVID-19-positive hip frac-
ture patients.
The NHFD has reported overall acute hospital length
of stay to be 15.1 days for the time period of March to
May 2019 [30]. The hospital length of stay (LOS) for pa-
tients in group PC was significantly longer compared to
LOS for patients in group C. This probably reflects a co-
ordinated effort to discharge patients more quickly dur-
ing the COVID-19 pandemic, in order to create
sufficient bed capacity to cope with the anticipated in-
flux of COVID-19-positive patients being admitted.
There was a significantly longer hospital stay for
COVID-19-positive patients compared to COVID-19-
negative patients. COVID-19-positive patients may have
required further clinical treatment, and care home facil-
ities were reluctant to accept COVID-19-positive pa-
tients back, until they had been in isolation for the
required period of time. A study conducted at a single
NHS hospital trust comprising 157 hip fracture patients
admitted in March to May 2020 showed similar findings;
approximate length of hospital stay for COVID-19-
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negative patients was lower at 12 days vs 17 days, al-
though not statistically significant [35]. Another multi-
centre UK study comprising 404 hip fracture patients
admitted in March 2020 again showed similar findings;
approximate length of hospital stay for COVID-19-
negative patients was statistically significantly lower at
14 days vs 18 days [36].
This study has its limitations inherent in any retro-
spective study design. Data on delayed complication
rates and revision rates of surgery were not available in
this short time period analysed. Whilst every attempt
has been made to check mortality rates using the ONS
database with local hospital records, deaths occurring
out of hospital may not have been identified because of
the short follow-up period, which may have led to an
underestimation of the mortality rate for these patients.
In addition, differences in mortality rates across hospi-
tals were observed. The reasons for this are unclear but
are likely to be multi-factorial and may reflect variation
in the incidence of COVID-19-positive patients in each
region. Finally, adjusted analyses were not conducted to
see how factors other than admission time period or
COVID-19 diagnosis may have played a role in mortality
rates. This study, however, has many strengths including
its multi-centre design covering a large part of England
outside of London. Nearly 600 consecutive patients were
analysed with a widespread distribution of their pre-
injury and peri-operative variables allowing a better
comparison of their management during the COVID-19
and pre-COVID-19 periods.
Conclusion
Despite the challenges COVID-19 has presented and
even though hip fractures patients during the COVID-19
pandemic experienced a longer time to theatre, it is re-
assuring to note that for these patients, the 30-day mor-
tality rate was similar to and the length of hospital stay
shorter than patients admitted in the same time period
prior to the pandemic.
However, when comparing patients who were COVID-
19 positive to those who were COVID-19 negative dur-
ing the pandemic, an even longer time to theatre, a sig-
nificantly longer hospital length of stay and a
significantly higher mortality rate were observed. This is
possibly due to changes in pre-operative and operative
procedures to treat COVID-19-positive patients [18, 37]
and delays in receipt of COVID-19 test results.
Whilst we recommend maintaining strict protocols to
minimise the risk for COVID-19 transmission, this
population of patients requires urgent care. It may be
useful to treat patients with an unknown COVID-19 sta-
tus as COVID-19-positive patients when theatre room
capacities allow for this to prevent surgical delays for pa-
tients with hip fractures.
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